Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07246590 · ClinicalTrials.gov registry record · Phase 3

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

A Phase 3 study of Warts and Common Warts, sponsored by Verrica Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
300
Enrollment target
6
Study locations

NCT07246590 is a Phase 3 study of Warts and Common Warts that is actively recruiting participants, run by Verrica Pharmaceuticals. The registered enrollment target is 300 participants, above the 179-participant average among 7 other Warts trials with a reported enrollment target (68% higher). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07246590, a Phase 3 study of Warts and Common Warts, is actively recruiting participants, sponsored by Verrica Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
300 participants
Enrollment target
6
Study locations

Study Summary

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.

Conditions Studied

Warts Common Warts Human Papilloma Virus (HPV) Common Warts (Verruca Vulgaris)

Interventions

  • COMBINATION_PRODUCT VP-102
  • COMBINATION_PRODUCT Vehicle

Study Locations (6)

Texas

  • The University of Texas Health Science Center at Houston - Houston
  • Texas Dermatology and Laser Specialists - San Antonio

Florida

  • Florida Center for Dermatology, P.A. - Saint Augustine

Indiana

  • The Indiana Clinical Trials Center, PC - Plainfield

Maryland

  • Anne Arundel Dermatology, PA dba Maryland Dermatology Laser Skin & Vein - Hunt Valley

Tennessee

  • Tennessee Clinical Research Center, Inc. - Nashville

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-12-17
Est. Completion 2027-06
Phase Phase 3

Sponsor

Verrica Pharmaceuticals

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07246590

The ClinicalTrials.gov registry entry for NCT07246590 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 179-participant average among 7 other Warts trials with a reported enrollment target (68% higher). The listed sponsor is Verrica Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Warts appearing as the primary indexed condition, and to 2 interventions - of which VP-102 is the first listed.

NCT07246590 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT07246590 about?

NCT07246590 is a clinical study titled "Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)". This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.

What is the current status of trial NCT07246590?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-12-17. Estimated completion is 2027-06.

What conditions does trial NCT07246590 study?

This clinical trial studies the following conditions: Warts, Common Warts, Human Papilloma Virus (HPV), Common Warts (Verruca Vulgaris).

What interventions are being tested in trial NCT07246590?

The interventions under investigation include: VP-102 (COMBINATION_PRODUCT), Vehicle (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT07246590?

This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07246590 being conducted?

This trial has 6 study locations across Florida, Indiana, Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Warts

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Warts

All registered trials for this condition

Common Warts

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.